Metabasis Type 2 Diabetes Candidate Successful In Phase IIa Study
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
After last year's disappointing Phase IIb results from a type 2 diabetes candidate, Metabasis Therapeutics is hoping for better luck with MB07803. The company said April 28 that the second-generation gluconeogenesis inhibitor met its primary efficacy endpoint in a Phase IIa study